Report
Jesper Birch-Jensen

iZafe Group - Dosell pre-orders to contribute from Q2-Q3’21e

450 Dosell pre-orders will contribute from late Q2’21e ‘21e lowered as H1 will likely be slower DCF fair value range of SEK 2.18-6.87/share (2.16-8.26)
Underlying
iZafe Group AB

iZafe Group AB Formerly known as MediRatt AB. iZafe Group AB, formerly MediRatt AB, is a Sweden-based company that conducts research, development and marketing of medical products for medication and drug management. Its offering includes Dosell, a patented drug dispenser under development that can be used when medicating patients at home via remote monitoring; and MediKoll, an app that provides patients information about side effects, reactions and allergies linked to different types of medication. The Company operates in the pharmaceutical industry, hospitals and care homes, and Pharmacies and private healthcare markets. It is active globally.

Provider
ABG Sundal Collier Sponsored
ABG Sundal Collier Sponsored

ABG Sundal Collier is the independent, Nordic investment banking powerhouse, developed over 30 years, founded on a hard working partnership culture and the ability to attract top talent.

Our strategy is to be an advisor and an intermediary, and the core product offering comprise corporate advisory services, corporate financing services and investor research and brokerage services.

Our corporate advisory team offers access to a broad financial and industrial network and unparalleled transaction experience. We provide financing to corporates through our superior Nordic and international distribution platform, and we are optimally structured for naturally matching trading flows, delivering best execution for clients.

The group employ approx. 250 staff working from the Nordic offices in Norway, Sweden and Denmark and in the offices in the key international markets US, UK and Germany. 


Analysts
Jesper Birch-Jensen

Other Reports on these Companies
Other Reports from ABG Sundal Collier Sponsored

ResearchPool Subscriptions

Get the most out of your insights

Get in touch